2,862 reports of this reaction
9.9% of all BRIMONIDINE TARTRATE reports
#1 most reported adverse reaction
TREATMENT FAILURE is the #1 most commonly reported adverse reaction for BRIMONIDINE TARTRATE, manufactured by Sandoz Inc. There are 2,862 FDA adverse event reports linking BRIMONIDINE TARTRATE to TREATMENT FAILURE. This represents approximately 9.9% of all 28,834 adverse event reports for this drug.
Patients taking BRIMONIDINE TARTRATE who experience treatment failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TREATMENT FAILURE is moderately reported among BRIMONIDINE TARTRATE users, representing a notable but not dominant share of adverse events.
In addition to treatment failure, the following adverse reactions have been reported for BRIMONIDINE TARTRATE:
The following drugs have also been linked to treatment failure in FDA adverse event reports:
TREATMENT FAILURE has been reported as an adverse event in 2,862 FDA reports for BRIMONIDINE TARTRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TREATMENT FAILURE accounts for approximately 9.9% of all adverse event reports for BRIMONIDINE TARTRATE, making it one of the most commonly reported side effect.
If you experience treatment failure while taking BRIMONIDINE TARTRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.